2018年5月24日(木) 15:20 〜 17:20 第9会場 (ロイトン札幌2F リージェント・ホール)

座長：饗場 郁子（独立行政法人国立病院機構東名古屋病院神経内科）, 池内 健（新潟大学脳研究所生命科学リソース研究センター）

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. The classic clinical presentation of PSP is now known as Richardson’s syndrome. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group (Mov Disord 32, 853, 2017). Several types of variant PSP syndrome were included in the new criteria. Importantly, diagnostic category of “suggestive of PSP” has newly developed to detect an early phase of PSP before massive functional disability appears. With disease-modifying therapies being developed, facilitating diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss the importance of early diagnosis and emerging therapeutic strategies for patients with PSP on the basis of new criteria for PSP diagnosis.